Ileal Bile Acid Transporter Inhibitors for Symptomatic Cholestasis due to Vanishing Bile Duct Syndrome in Adults Authors: Anthony Vignone, Domenico Montecalvo, Paola Ferrari, Silvia Nardelli, Simone Di Cola, Giulia D'Amati, Andrea Ascione, Stefano Ginanni Corradini, Simona Parisse, Flaminia Ferri, Antonio Sili Scavalli, Domenico Alvaro, Vincenzo Cardinale Published: 2026 ABSTRACT ABSTRACTVanishing bile duct syndrome (VBDS) is a rare cholangiopathy that may follow drug-induced liver injury and can progress to liver failure. No established pharmacological treatment is currently available. We present a case of a 65-year-old man diagnosed with histologically confirmed and progressive symptomatic VBDS, probably sustained by drug-induced liver injury, who was successfully treated with a 4-week course of off-label ileal bile acid transporter inhibitor treatment of the management of pruritus. To our knowledge, this is among the first reports of successful ileal bile acid transporter inhibitor use in VBDS. This case highlights the potential role of bile acid modulation in managing severe symptomatic VBDS and underscores the importance of a proactive, multidisciplinary approach to optimize outcomes in complex cholangiopathies. INTRODUCTION Cholangiopathies are a heterogeneous spectrum of diseases affecting cholangiocytes, the cells lining the biliary epithelium and peribiliary glands. Among these, vanishing bile duct syndrome (VBDS) is a rare idiosyncratic cholangiopathy involving small intrahepatic bile ducts, potentially leading to liver transplantation and with no approved medical treatment. In elderly patients, idiosyncratic drug-induced liver injury (DILI) often presents as drug-induced cholestasis, potentially leading to cholangiopathy and life-threatening VBDS. We report a patient with VBDS successfully treated with an ileal bile acid transporter (IBAT) inhibitor for severe pruritus. CASE REPORT A 65-year-old Italian man presented to the Emergency Department with a 3-day history of general asthenia, jaundice, and hyperchromic urines. In his medical history, he had no major comorbidities, except for the Bell palsy approximately 2 months before presentation, which was treated with high-dose corticosteroids (up to 80 mg/d of methylprednisolone), acetyl-l-carnitine, and a multi-ingredient supplement containing palmitoylethanolamide, bromelain, and alpha-lipoic acid (exact composition and dosage not fully available). These treatments were initiated approximately 4–6 weeks before symptom onset and discontinued before admission. He denied recent travel, high-risk sexual behaviors, alcohol intake, and recreational drug use. However, he is a farmer with long-term occupational exposure to unspecified pesticides. On presentation, he was afebrile (36.7°C) and jaundiced, with hyperchromic urine and normochromic stools. Initial laboratory findings revealed a mild elevation of liver injury markers (aspartate aminotransferase [AST]/alanine transaminase [ALT] 127/96 U/L, normal <40 U/L), a rise in cholestatic enzymes (gamma-glutamyl transferase [GGT] 123 U/L normal < 60 U/L, alkaline phosphatase [ALP] 244 normal <120 U/L, total bilirubin 26 mg/dL, direct bilirubin 22.4 mg/dL), normal blood count, and liver function indices (prothrombin time [PT] international normalized ratio, albumin, pseudokinesterase). Based on these laboratory results, the patient was admitted to the Gastroenterology Department of the same hospital. Investigations into possible causes of acute liver damage were conducted: autoimmunity was negative, serology for major hepatotropic viruses was negative, and serology for minor hepatotropic viruses showed a positive IgM cytomegalovirus (CMV) and CMV DNA of 38,797 copies/mL. Abdominal ultrasound and magnetic resonance cholangiopancreatography were unremarkable. Liver biopsy revealed microvesicular steatosis, mild periportal chronic inflammation, and features of intrahepatocellular cholestasis. Due to CMV DNA positivity and the alteration of cholestasis indices, valganciclovir therapy and ursodeoxycholic acid (UDCA) was initiated. Initially, there was a reduction in bilirubin values to 18 mg/dL, which subsequently remained stable, along with stability in the values of liver cytonecrosis indices. However, as the tests failed to normalize, the patient was transferred to the gastroenterology department of our liver transplant center, approximately 3 weeks after admission to the Emergency Department. Upon admission to our department, hematological examinations were repeated, showing persistently elevated liver cytonecrosis indices (AST/ALT 127/88 U/L), cholestasis (GGT 264 U/L, ALP 101 U/L), total bilirubin 16.4 mg/dL, and direct bilirubin 14.8. The CMV DNA assay was repeated and found to be negative, magnetic resonance cholangiopancreatography was repeated with negative results, and a new liver needle biopsy was performed (Figure 1). Histological reevaluation, including direct comparison between the initial and the second liver biopsy, documented a progression of liver injury. The first biopsy showed mild portal inflammation, in association with prominent intrahepatocellular and canalicular cholestasis. By contrast, the second biopsy demonstrated a marked increase in portal and lobular inflammatory activity, with the appearance of interface hepatitis and more pronounced cholestatic features, including bile plugs and advanced hepatocellular feathery degeneration. Cytokeratin 7 (CK7) immunostaining highlighted significant bile duct loss, with approximately two-thirds of portal tracts lacking an interlobular bile duct, consistent with ductopenia. In addition, considering the possibility of DILI due to multiple agents, the Updated Roussel Uclaf Causality Assessment Method (RUCAM) for cholestatic/mixed injury was applied, considering the combination of medications. The resulting RUCAM score was 8, indicating a probable association. Histology of the 2 liver biopsies performed in the span of 3 months. (A and B) The first biopsy showed mild mononuclear inflammation of the portal tracts (black asterisks), with no signs of damage to the bile ducts and no interface hepatitis. There was significant canalicular and intracytoplasmic bile stasis (black arrows), with initial feathery degeneration of hepatocytes (black arrowhead). (Hematoxylin and eosin, original magnification: A 20×; B 40×). (C and D) The second biopsy, performed 3 months after the first one, showed intense portal inflammatory infiltrate (white arrowheads) composed by lymphocytes, granulocytes and some plasma cells, in association with moderate interface hepatitis (white arrows). There was also centrilobular inflammation (white asterisks) and remarkable canalicular and intracytoplasmic bile stasis (black diamonds), with formation of large bile plugs and advanced feathery degeneration of hepatocytes. (Hematoxylin and eosin, original magnification: C 20×; D 40×). As laboratory values showed spontaneous improvement, the patient was discharged and followed up with periodic outpatient testing. Owing to the lack of improvement in hematological tests (total bilirubin 9.89 mg/dL, AST 199 U/L, ALT 176 U/L, GGT 296 U/L, ALP 298 U/L) and persistent itching (pruritus was rated as 7 out of 10 on the Visual Analogue Scale), a next-generation sequencing panel for hereditary cholestasis was performed. The targeted panel included full sequencing of coding regions and intron-exon boundaries of more than 30 cholestasis-related genes. The analysis revealed a heterozygous UDP glucuronosyltransferase 1 family member A1 variant, classified as likely benign/low risk. Odevixibat (a reversible, selective IBAT inhibitor) was initiated at 2.4 mg/d (∼40 µg/kg), while UDCA was continued. In the following weeks, there was marked improvement in pruritus (3/10 on the Visual Analogue Scale score) and normalization of intrahepatic and extrahepatic cholestasis enzymes and improvement in liver cytonecrosis indices (Figures 2–4). At 24 months of follow-up, the patient remained clinically stable, with complete resolution of pruritus and sustained normalization of liver biochemistry. Serial laboratory assessments, including those performed outside our center and subsequently reviewed, showed no evidence of biochemical relapse. Changes in total and direct bilirubin from admission to day 121 with introduction of ursodeoxycholic acid and odevixibat. Changes in cholestatic indices from admission to day 121 with introduction of ursodeoxycholic acid and odevixibat. ALP, alkaline phosphatase; GGT, gamma-glutamyl transferase. Changes in aspartate aminotransferase and alanine transaminase levels from admission to day 121 with introduction of ursodeoxycholic acid and odevixibat. GOT, glutamic oxaloacetic transaminase; GPT, glutamic pyruvic transaminase. DISCUSSION Drug-induced cholestasis represents 20%–40% of cases of idiosyncratic DILI, according to various registries.1 Patients with drug-induced cholestasis are typically older than those with hepatocellular or mixed patterns, and recovery is usually slower. Histologically, drug-induced cholestasis may present as cholestatic hepatitis, VBDS, acute or chronic cholestasis, and immune checkpoint inhibitor-associated cholangiopathies. The latter includes immune-mediated large-duct cholangitis, small-duct cholangitis, and cholecystitis, which have been observed following treatment with anti-programmed cell death ligand-1 (anti-PD-L1) and anti-programmed cell death protein 1 (anti-PD-1) immune checkpoint inhibitors.1 Drugs most frequently implicated include antibiotics (especially amoxicillin–clavulanate), nonsteroidal anti-inflammatory drugs, and statins.1,2 Diagnosis remains one of exclusion and requires careful pharmacological history, temporal correlation between exposure and onset, and exclusion of competing causes such as viral hepatitis, autoimmune disease, or metabolic cholestatic disorders.2,3 The RUCAM score is a widely used structured tool that estimates the probability of a causal relationship. It systematically considers various factors, including the temporal relationship between drug intake and liver injury onset, the course of liver enzyme levels after drug withdrawal, concomitant drug use, risk factors, and previous reports of hepatotoxicity with the suspected drug.4 Currently, there is no targeted medical therapy for cholestatic DILI; management primarily involves discontinuing the suspected drug, avoiding re-exposure, and addressing symptoms.2,3 UDCA is sometimes prescribed, but evidence supporting its effectiveness in cholestatic DILI is limited. However, it may help in cholestatic liver disease by mitigating bile salt toxicity, enhancing hepatobiliary secretion, providing antioxidant effects, increasing glutathione levels, and reducing liver cell apoptosis.5,6 Severe cholestasis-related pruritus can be managed with cholestyramine, antihistamines, rifampicin, phenobarbital, and opioid receptor modulators.2 Recent advancements in drug molecular characterization and insights into hepatocyte and cholangiocyte protein functions have clarified the mechanisms behind many cases of drug-induced cholestasis previously considered idiopathic cholestasis and have led to reduced clinical complications from idiosyncratic DILI. The liver plays a fundamental role in the elimination of lipophilic drugs and their metabolites through biliary excretion, and many drugs can induce cholestasis by interacting with hepatic transporters.7 Interestingly, the mechanisms underlying drug-induced cholestasis involve altered bile transporters and immunologic responses.8 For instance, VBDS, a ductular form of idiosyncratic DILI, can occur when a drug or its metabolite induces an immune response against bile duct cells. The process of clearing drugs and their metabolites is largely regulated by adenosine triphosphate (ATP)-dependent transporters in the bile canaliculi, specifically members of the multidrug resistance-associated protein (MRP) family. These include the bile salt export pump encoded by the ABCB11 gene, which handles bile salt transport, and multidrug resistance-associated protein 2 (MRP2) encoded by the ABCC2 gene, which mediates bile salt-independent flow by exporting glutathione conjugates.9 Other critical transporters are multidrug resistance protein 1 (MDR1) encoded by the ABCB1 gene, which transports various organic cations, and multidrug resistance protein 3 (MDR3) encoded by the ABCB4 gene, which is responsible for phospholipid transport.8 Mutations in ABCB11 and ABCB4 are historically linked to progressive familial intrahepatic cholestasis (PFIC) types 2 and 3.10 In addition, single or compound heterozygous mutations in these genes contribute to a range of conditions, including benign recurrent intrahepatic cholestasis, intrahepatic cholestasis of pregnancy, low-phospholipid-associated cholelithiasis, and certain cases of drug-induced cholestasis. By contrast, ABCC2 gene mutations result in MRP2 deficiency, leading to Dubin-Johnson syndrome, which is characterized by conjugated hyperbilirubinemia and liver pigmentation.11 MRP2 defects also reduce bile flow, exacerbating cholestasis and increasing susceptibility to drug-induced cholestasis by limiting the hepatocyte clearance of xenobiotics and drug metabolites.12Finally, the P-glycoprotein transporter MDR1, encoded by the ABCB1 gene, is involved in moving a wide variety of substances and is notable for conferring multidrug resistance in cancer cells by actively expelling various chemotherapeutics. It also influences the pharmacokinetics of various lipophilic drugs, including alkaloids, flavonoids, and other hydrophobic natural toxins.13 According to the most recent guidelines, genetic testing for cholestatic liver disease is recommended in adults once more common causes have been excluded, particularly in cases with atypical features or poor response to initial treatment. Next-generation sequencing and whole-exome sequencing are the preferred diagnostic approaches.14 IBATs play a crucial role in the enterohepatic circulation of bile acids, regulating their absorption from the intestine and their return to the liver.15 This intricate process is essential for the maintenance of bile acid homeostasis and overall liver function.16 Among the emerging pharmacological agents targeting IBATs, odevixibat has garnered significant attention for its potential in treating cholestatic liver disorders. odevixibat is a reversible, potent, and selective IBAT inhibitor. In the PICTURE trial, it significantly reduced serum bile acids and improved pruritus in patients with PFIC, leading to its approval in 2022.17 Moreover, odevixibat has also been approved for the treatment of cholestatic pruritus in patients with Alagille syndrome.18 In addition, the drug is currently under investigation in the phase III BOLD study for biliary atresia, with primary completion expected in 2026.19 Although odevixibat is currently approved for genetically driven cholestatic diseases such as PFIC and Alagille syndrome, and is under investigation for biliary atresia, its mechanism as an IBAT inhibitor may also offer therapeutic benefit in acquired cholestatic conditions. In our case of drug-induced cholestasis, off-label use of odevixibat was associated with clinical and biochemical improvement, suggesting a potential role for bile acid modulation in managing severe cholestatic pruritus and bile acid overload in drug-induced cholestasis. Further studies are warranted to evaluate this potential indication. Experience with odevixibat use in adults is very limited. A notable case involves a 35-year-old man who presented with liver cirrhosis and a history of unspecified cholestatic liver disease, characterized by severe pruritus and elevated bile acids. Despite inconclusive genetic tests, treatment with odevixibat was initiated, resulting in pruritus improvement and slowing of disease progression.20 Additional data were collected from 10 other adult patients diagnosed with genetic cholestasis. In all cases, pruritus was the primary indication for odevixibat use. Remarkably, 8 out of 10 patients experienced complete resolution of pruritus, with only 2 reporting mild gastrointestinal side effects.21 Maralixibat is an IBAT inhibitor currently approved for the treatment of cholestatic pruritus in patient with Alagille syndrome aged over 2 months, as well as in those with PFIC.22 In PFIC, maralixibat has been shown to improve pruritus and biomarkers associated with native liver survival, such as serum bile acid levels. This case highlights the use of odevixibat, an IBAT inhibitor, for severe symptomatic VBDS likely induced by DILI. Idiosyncratic DILI may follow a prolonged but self-limiting course, and the biochemical improvement observed in our patient cannot be definitively attributed to odevixibat. Nevertheless, the rapid relief of pruritus after treatment initiation, together with the parallel improvement in cholestatic parameters, is noteworthy. Bile acid modulation may represent a promising therapeutic approach for managing cholestatic pruritus and bile acid overload in acquired cholangiopathies. Further studies are warranted to better define efficacy, optimal dosing, and safety in adult patients. DISCLOSURES Author contributions: A. Vignone and SD Cola drafted the manuscript. SD Cola and A. Ascione performed and interpreted the histological analysis and provided the pathological descriptions. SG Corradini. S. Parisse, F. Ferri and AS Scavalli contributed to patient management during hospitalization and clinical data collection. S. Nardelli, V. Cardinale, A. Vignone, and D. Montecalvo were involved in outpatient management and clinical follow-up. V. Cardinale and D. Alvaro supervised the study. V. Cardinale is the article guarantor. Acknowledgments: We thank the staff of the Gastroenterology Department, Policlinico Umberto I, Sapienza University of Rome, for their valuable support in patient care. Financial disclosure: None to report. Informed consent was obtained for this case report.